Editas Medicine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

Gilmore O’Neill

CEOGilmore O’Neill

Employees

Employees87

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2013

Founded2013

Employees

Employees87

EDIT Key Statistics

Market cap

260.83M

Market cap260.83M

Price-Earnings ratio

-1.41

Price-Earnings ratio-1.41

Dividend yield

—

Dividend yield—

Average volume

2.42M

Average volume2.42M

High today

$2.70

High today$2.70

Low today

$2.55

Low today$2.55

Open price

$2.61

Open price$2.61

Volume

1.97M

Volume1.97M

52 Week high

$4.54

52 Week high$4.54

52 Week low

$0.9101

52 Week low$0.9101

Stock Snapshot

The current Editas Medicine(EDIT) stock price is $2.60, with a market capitalization of 260.83M. The stock trades at a price-to-earnings (P/E) ratio of -1.41.

During the trading session on 2026-03-12, Editas Medicine(EDIT) shares reached a daily high of $2.70 and a low of $2.55. At a current price of $2.60, the stock is +2.0% higher than the low and still -3.7% under the high.

Trading activity shows a volume of 1.97M, compared to an average daily volume of 2.42M.

Over the past 52 weeks, Editas Medicine(EDIT) stock has traded between a high of $4.54 and a low of $0.91.

EDIT News

TipRanks 1d

Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects

Editas Medicine Inc. (EDIT) has disclosed a new risk, in the Regulation category. Disruptions at the FDA and other government agencies could materially slow Ed...

TipRanks 2d

Editas Medicine upgraded to Buy from Hold at JonesResearch

JonesResearch analyst Soumit Roy upgraded Editas Medicine (EDIT) to Buy from Hold with an $8 price target With Editas nearing IND/CTA submission of their hetero...

Nasdaq 3d

Editas Medicine Reports Q4 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $1 per...

Analyst ratings

56%

of 9 ratings

Buy

55.6%

Hold

33.3%

Sell

11.1%

More EDIT News

TipRanks 3d

Editas Medicine reports Q4 EPS (6c), consensus (26c)

Reports Q4 revenue $24.741M vs $30.604M last year. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become...

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

CRISPR

Intellia Therapeutics

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.